Across TCGA pan-cancer cohorts, ATL1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATL1 data layer compared with 23 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATL1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
LUAD, CCRCC, and GBM are the cancer types where ATL1 mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.